Literature DB >> 17898521

The ICTUS Study: A Prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort.

E Reynish1, F Cortes, S Andrieu, C Cantet, M Olde Rikkert, R Melis, L Froelich, G B Frisoni, L Jönsson, P J Visser, P J Ousset, B Vellas.   

Abstract

The long-term objective of the ICTUS study is to identify milestones in Alzheimer's disease (AD) progression and to develop a model to predict disease course in individual AD patients in Europe. The secondary objectives are to describe the patterns of prescribing, and the socioeconomic impact of AD in Europe. Between 2003 and 2005 1,380 patients with probable AD were recruited in specialised (secondary care) clinics in 12 European countries. Their mean age was 76 years and they had a mean of 8.0 +/- (SD) 4.6 years of education. Thirty-five percent were male. The mean MMSE score was 20.4 +/- (SD) 4.0. Forty-three percent had very mild dementia (CDR 0.5) and 44% had mild dementia (CDR 1). All patients completed baseline evaluation and biannual follow-up is ongoing. The goals of the current study are to describe the specific methods for recruitment in this crosscultural setting and the characteristics of the inception ICTUS cohort, including clinical features, co-morbidity, neuropsychological performance, neuropsychiatric symptoms, functional impairment and social burden. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17898521     DOI: 10.1159/000108915

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  18 in total

1.  Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Authors:  Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2019-06-01       Impact factor: 21.566

2.  A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.

Authors:  Virginie Gardette; Maryse Lapeyre-Mestre; Antoine Piau; Adeline Gallini; Christelle Cantet; Jean-Louis Montastruc; Bruno Vellas; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

3.  Assessing attitudes and behaviours surrounding Alzheimer's disease in Europe: key findings of the Important Perspectives on Alzheimer's Care and Treatment (IMPACT) survey.

Authors:  R W Jones; J Mackell; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

4.  Physicians and caregivers: ready and waiting for increased participation in clinical research.

Authors:  R W Jones; S Andrieu; S Knox; J Mackell
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

5.  Health and nutrition promotion program for patients with dementia (NutriAlz): cluster randomized trial.

Authors:  A Salvà; S Andrieu; E Fernandez; E J Schiffrin; J Moulin; B Decarli; X Rojano-i-Luque; Y Guigoz; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

6.  Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!

Authors:  François Montastruc; Virginie Gardette; Christelle Cantet; Antoine Piau; Maryse Lapeyre-Mestre; Bruno Vellas; Jean-Louis Montastruc; Sandrine Andrieu
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

7.  Health and nutritional promotion program for patients with dementia (NutriAlz Study): design and baseline data.

Authors:  A Salva; S Andrieu; E Fernandez; E J Schiffrin; J Moulin; B Decarli; Y Guigoz; B Vellas
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

8.  Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).

Authors:  Seyed-Mohammad Fereshtehnejad; Kristina Johnell; Maria Eriksdotter
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

9.  Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.

Authors:  Marco Canevelli; Nawal Adali; Christelle Cantet; Sandrine Andrieu; Giuseppe Bruno; Matteo Cesari; Bruno Vellas
Journal:  J Neurol       Date:  2013-03-17       Impact factor: 4.849

10.  The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium.

Authors:  Giovanni B Frisoni; Wouter J P Henneman; Michael W Weiner; Philip Scheltens; Bruno Vellas; Emma Reynish; Jaroslava Hudecova; Harald Hampel; Katharina Burger; Kaj Blennow; Gunhild Waldemar; Peter Johannsen; Lars-Olof Wahlund; Giancarlo Zito; Paolo M Rossini; Bengt Winblad; Frederik Barkhof
Journal:  Alzheimers Dement       Date:  2008-07       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.